PARP1 and cancer: Unsurprisingly, we observed intra- and inter-tumoral differential sensitivity to PARP inhibition in pediatric cancer cell lines, highlighting the necessity for both novel combinations to improve efficacy and biomarkers to select sensitive phenotypes.